CPT® Code 90739

The CPT® Code 90739 refers to the Hepatitis B vaccine (HepB), specifically the CpG-adjuvanted formulation intended for adult use. This vaccine is administered intramuscularly and is available in either a 2-dose or a 4-dose schedule. Unlike immune globulins, which offer short-term, passive immunity, vaccines like the Hepatitis B vaccine provide active, long-term immunity. This is achieved by exposing the recipient's immune system to modified versions of the hepatitis B virus, prompting the immune system to produce its own antibodies. As a result, the body retains the ability to generate these antibodies upon subsequent exposure to the virus, thereby offering protection against hepatitis B, a chronic liver disease that can lead to severe health complications, including hospitalization and death. The Hepatitis B vaccine is significant not only for its role in preventing the disease but also for its potential to avert long-term consequences such as hepatocellular carcinoma, making it one of the pioneering cancer vaccines in clinical use. The vaccine can be derived from the blood plasma of asymptomatic carriers or produced through recombinant technology, where a plasmid containing the hepatitis gene is inserted into common baker's yeast. This yeast is then lysed, and the components are purified for use in the vaccine. It is important to note that the codes associated with the Hepatitis B vaccine, including code 90739, specifically report the vaccine product itself for intramuscular administration, while the actual injection procedure is reported separately. The CpG-adjuvanted HepB vaccine represents a single antigen vaccine enhanced with a new class of stimulant designed to boost the immune response to the hepatitis B antigen.